Xiidra is a Ophthalmic Solution/ Drops in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Lifitegrast.
Product ID | 0078-0911_1de81040-6b02-4632-afec-bde1e05391da |
NDC | 0078-0911 |
Product Type | Human Prescription Drug |
Proprietary Name | Xiidra |
Generic Name | Lifitegrast |
Dosage Form | Solution/ Drops |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2016-07-11 |
Marketing Category | NDA / NDA |
Application Number | NDA208073 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | LIFITEGRAST |
Active Ingredient Strength | 50 mg/mL |
Pharm Classes | Lymphocyte Function-Associated Antigen-1 Antagonist [EPC],Lymphocyte Function-Associated Antigen-1 Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2020-06-04 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0911 | Xiidra | Lifitegrast |
54092-606 | Xiidra | Lifitegrast |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
XIIDRA 87319276 5271076 Live/Registered |
SARcode Bioscience Inc. 2017-01-31 |
XIIDRA 86056637 5050074 Live/Registered |
SARcode Bioscience Inc. 2013-09-05 |
XIIDRA 79293316 not registered Live/Pending |
NOVARTIS AG 2020-06-29 |